13th Mar 2025 Plain language summary of the FLAURA2 study: Impact of first-line osimertinib plus chemotherapy on brain health in patients with EGFR-mutated advanced non-small cell lung cancer
25th Feb 2025 A plain language summary of the FLAURA2 study results: First-line osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC
1st Nov 2021 A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
